Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Using an API to commercialize an evidence based weight loss intervention

    SBC: COEUS HEALTH, LLC            Topic: 300

    DESCRIPTION provided by applicant Over percent of the U S population is currently overweight or obese percent are obese Obesity is a primary cause of numerous chronic diseases including type II diabetes cancer heart disease and the metabolic syndrome Behavioral weight loss interventions have successfully resulted in significant clinical improvements in weight percent weight lo ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome

    SBC: ATHERSYS, INC.            Topic: NIAAA

    DESCRIPTION provided by applicant This is a resubmission of a Phase I Phase II Fast Track application for the clinical use of MultiStem in patients with acute respiratory distress syndrome ARDS ARDS is defined as acute onset hypoxemia bilateral radiographic pulmonary infiltrates and lack of atrial pressure hypertension A novel and exiting possibility is the use of cells as part of the ther ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Newborn Infant Vision Test

    SBC: Precision Vision, Inc.            Topic: N

    Project Summary! This STTR Phase II project continues the development of the Newborn Acuity Cardstm and the Newborn Contrast Cardstm Together these Newborn Cards form a new clinical test of visual acuity and contrast sensi tivity for use on newborn full term and preterm infants The stimuli are square wave gratings which the examiner presents to the infant in a fixation and following protocol ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Aminomethyl benzamides as novel anti Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenes ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Better Living After Stroke through Technology BLAST

    SBC: BRIGHTOUTCOME INC.            Topic: 600

    DESCRIPTION provided by applicant Stroke the leading cause of disability cognitive impairment and death in the US imposes significant financial and personal burden The residual effects of stroke affect many aspects of life not addressed by traditional rehabilitation treatments In particular persons with mild stroke typically defined as a stroke with no or sligh motor impairment and a high ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Aminopiperidines as novel anti influenza agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Influenza A viruses belong to the orthomyxoviridae family with a negative sense segmented RNA genome which can cause seasonal or pandemic flu with high morbidity and significant mortality Vaccination is the most prevalent prophylactic means for controlling influenza infections However an effective vaccine usually takes at least months to develop for the circulating strains Furthermore vac ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With mTc Tilmanocept

    SBC: Navidea Biopharmaceuticals, Inc.            Topic: 102

    DESCRIPTION provided by applicant Navidea Biopharmaceuticals has developed mTc tilmanocept as a radiopharmaceutical diagnostic imaging agent targeted to the macrophage mannose receptor CD to be used as an aid for lymphatic mapping in cancer surgeries The United States Food and Drug Administration approved Navideaandapos s new drug application NDA for mTc Tilmanocept for use in surge ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Regulatory Approval of the OLFACT Test Battery

    SBC: OSMIC ENTERPRISES, INC.            Topic: NIA

    DESCRIPTION provided by applicant Although there are numerous scientific studies in the literature that show impairments in olfaction often occur early in the onset of Alzheimerandapos s Disease AD there is still concern pertaining to the specificity of measures of olfactory dysfunction when used as a predictor of AD For this and other reasons there is no test based upon measures of olfact ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Salud Juntos A Promotora Led Home Based Cancer Care Support Solution

    SBC: BRIGHTOUTCOME INC.            Topic: 102

    DESCRIPTION provided by applicant This application is in response to RFA EB a special SBIR program to reduce health disparities by developing medical technologies that are andquot effective affordable culturally acceptable and easily accessible to those who need them andquot It is based on the well established partnership between BrightOutcome and Dr Ana Maria Lopez Associate Vice ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Biomaterial augmented microfracture repair of full thickness chondral defects

    SBC: ISTO TECHNOLOGIES            Topic: NIAMS

    DESCRIPTION provided by applicant The goal of this project is to provide a synthetic biomaterial capable of giving long term repair of full thickness chondral lesions with the aim of helping to reduce the joint replacements carried out each year in the USA Our company has developed a synthetic biomaterial technology with proven biocompatibility in treating over patients for bon ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government